search
Back to results

Venetoclax and Lintuzumab-Ac225 in AML Patients

Primary Purpose

Acute Myeloid Leukemia, Relapsed Adult AML

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Lintuzumab-Ac225
Venetoclax
Spironolactone
Sponsored by
Actinium Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Lintuzumab-Ac225, Venetoclax, Lintuzumab, Refractory AML

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Refractory or relapsed AML which will include:

    1. Refractory disease will be defined as at least 1 prior treatment with no remission.
    2. Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission.
    3. Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible.
  2. Circulating blast count ≤ 200/μL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count ≤ 200/μL until the first day of protocol treatment, to the extent that this is possible
  3. ECOG ≤ 2
  4. Estimated creatinine clearance ≥ 50 mL/min
  5. AST and ALT ≤ 3.0 x ULN
  6. Bilirubin ≤ 3.0 x ULN

Exclusion Criteria:

  1. Active CNS Leukemia.
  2. Known HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load).
  3. Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment.
  4. Secondary refractory AML (e.g., treated for current relapse without achieving remission);

    a. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission.

  5. Have received prior radiation to maximally tolerated levels to any critical normal organ.
  6. Clinically significant cardiac disease.
  7. Active, uncontrolled serious infection.
  8. Have other non-myeloid malignancy within 2 years of entry (with exceptions).
  9. Psychiatric disorder that would preclude study participation
  10. Previous solid organ transplant (prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression/GVHD therapy).

Sites / Locations

  • University of CaliforniaRecruiting
  • University of LouisvilleRecruiting
  • Ochsner Clinic FoundationRecruiting
  • Weill Cornell MedicineRecruiting
  • Fred Hutchinson Cancer Research CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Phase I and Phase II

Arm Description

Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review). Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery.

Outcomes

Primary Outcome Measures

Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225
To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapse/refractory AML.
Phase II: Overall Response (CR + CRh + CRi)
To assess the percentage of patients with CR, CRh, CRi or Overall Response (CR + CRh + CRi), up to 6 months after the start of treatment without receiving other AML therapies.

Secondary Outcome Measures

Phase I: Overall Response
Number of patients who's overall response is CR, CRh, or CRi
Phase I and II: OS
Number of patients who died
Phase I and II: DFS
Disease-free survival
Phase I and II: Evaluate incidence of AEs and SAEs
Rate of AEs and SAEs, including infusion-related reactions
Phase I and II: Evaluate BH3 priming assay results
Summary of assay results
Phase I and II: MRD status
Number of patients who are MRD negative
Phase I and II: Lab abnormalities (other than hematologic indices)
Summary of rate of Grade 3/4 lab abnormalities

Full Information

First Posted
March 6, 2019
Last Updated
August 2, 2023
Sponsor
Actinium Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT03867682
Brief Title
Venetoclax and Lintuzumab-Ac225 in AML Patients
Official Title
A Phase I/II Study of Venetoclax and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 15, 2020 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Actinium Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study is a multicenter, open label Phase I/II trial. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Detailed Description
The study is a multicenter, open label Phase I and Phase II trial combining lintuzumab-Ac225 with venetoclax in patients who have relapsed or refractory AML. The Phase I portion is a dose-finding study which will enroll at least three patients at each dose level. Patients in a dose level will be observed for a minimum of 4 weeks before dose escalation occurs. There is no dose escalation for any individual patient. The Phase II portion of the study will enroll patients at the MTD dose level of lintuzumab-Ac225 as determined in the Phase I portion of the study. The goal of the Phase II portion will be to further characterize the safety and efficacy of the MTD dose of lintuzumab-Ac225.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myeloid Leukemia, Relapsed Adult AML
Keywords
Lintuzumab-Ac225, Venetoclax, Lintuzumab, Refractory AML

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase I and Phase II
Arm Type
Experimental
Arm Description
Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review). Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery.
Intervention Type
Biological
Intervention Name(s)
Lintuzumab-Ac225
Other Intervention Name(s)
Actimab
Intervention Description
In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
Intervention Type
Drug
Intervention Name(s)
Venetoclax
Other Intervention Name(s)
Venclexta
Intervention Description
400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
Intervention Type
Drug
Intervention Name(s)
Spironolactone
Other Intervention Name(s)
Aldactone
Intervention Description
25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
Primary Outcome Measure Information:
Title
Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225
Description
To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapse/refractory AML.
Time Frame
Cycle 1, up to 48 days
Title
Phase II: Overall Response (CR + CRh + CRi)
Description
To assess the percentage of patients with CR, CRh, CRi or Overall Response (CR + CRh + CRi), up to 6 months after the start of treatment without receiving other AML therapies.
Time Frame
Up to 6 months
Secondary Outcome Measure Information:
Title
Phase I: Overall Response
Description
Number of patients who's overall response is CR, CRh, or CRi
Time Frame
Up to 6 months
Title
Phase I and II: OS
Description
Number of patients who died
Time Frame
End of 6 months, 12 months, 2 years
Title
Phase I and II: DFS
Description
Disease-free survival
Time Frame
End of 6 months, 12 months, 2 years
Title
Phase I and II: Evaluate incidence of AEs and SAEs
Description
Rate of AEs and SAEs, including infusion-related reactions
Time Frame
Through study completion, up to 2 years
Title
Phase I and II: Evaluate BH3 priming assay results
Description
Summary of assay results
Time Frame
Completion of Cycle 1, estimated 1 month
Title
Phase I and II: MRD status
Description
Number of patients who are MRD negative
Time Frame
From date of first dose until the date of first documented response, first assessment at 6 months
Title
Phase I and II: Lab abnormalities (other than hematologic indices)
Description
Summary of rate of Grade 3/4 lab abnormalities
Time Frame
Through study completion, up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Refractory or relapsed AML which will include: Refractory disease will be defined as at least 1 prior treatment with no remission. Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission. Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible. Circulating blast count ≤ 200/μL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count ≤ 200/μL until the first day of protocol treatment, to the extent that this is possible ECOG ≤ 2 Estimated creatinine clearance ≥ 50 mL/min AST and ALT ≤ 3.0 x ULN Bilirubin ≤ 3.0 x ULN Exclusion Criteria: Active CNS Leukemia. Known HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load). Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment. Secondary refractory AML (e.g., treated for current relapse without achieving remission); a. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission. Have received prior radiation to maximally tolerated levels to any critical normal organ. Clinically significant cardiac disease. Active, uncontrolled serious infection. Have other non-myeloid malignancy within 2 years of entry (with exceptions). Psychiatric disorder that would preclude study participation Previous solid organ transplant (prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression/GVHD therapy).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Actinium Pharmaceuticals, Inc.
Phone
+1-646-677-3878
Email
actimab@actiniumpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Avinash Desai, MD
Organizational Affiliation
Actinium Pharmaceuticals, Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
University of California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Recruiting
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Individual Site Status
Recruiting
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
33347715
Citation
Garg R, Allen KJH, Dawicki W, Geoghegan EM, Ludwig DL, Dadachova E. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Med. 2021 Feb;10(3):1128-1140. doi: 10.1002/cam4.3665. Epub 2020 Dec 21.
Results Reference
derived

Learn more about this trial

Venetoclax and Lintuzumab-Ac225 in AML Patients

We'll reach out to this number within 24 hrs